Kevin Young: Gilead

Corporate Overview

Leadership
Executive Committee
John C. Martin John F. Milligan Norbert W. Bischofberger Kevin Young Gregg H. Alton Anthony D. Caracciolo Paul Carter Seigo Izumo William A. Lee Kristen M. Metza James R. Meyers A. Bruce Montgomery John J. Toole Robin L. Washington Taiyin Yang
Board of Directors Scientific Advisory Board

Worldwide Operations

Corporate Responsibility

Partners and Business Development

Kevin Young

Executive Vice President, Commercial Operations

Kevin Young joined Gilead Sciences in 2004 as Executive Vice President of Commercial Operations. Mr. Young has 25 years of experience in the biopharmaceutical industry, holding positions previously at Amgen, Inc. and Zeneca Pharmaceuticals (formerly ICI Pharmaceuticals). During his 12 years at Amgen, Mr. Young held a number of positions in Europe and the United States, most recently as Head of the U.S. Inflammation Business Unit leading the re-launch of Enbrel® following the acquisition of Immunex Corporation.

Mr. Young is a member of the board of Interplast, the first international humanitarian organization to provide free reconstructive plastic surgery in developing countries.

Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise from Liverpool John Moores University and Nottingham University in England and has completed the Executive Program at the University of Michigan.